Nomination Committee’s proposal for election of Board members 2023

The Nomination Committee of Boule Diagnostics AB has decided to propose to the Annual General Meeting 2023 (AGM) that the number of Board members shall be six, including the Chair. The Nomination Committee proposes the re-election of Karin Dahllöf, Thomas Eklund, Emil Hjalmarsson, Torben Jørgensen, Yvonne Mårtensson and Jon Risfelt as Board members, and the election of Torben Jørgensen as the Chairman of the Board.

Torben Jørgensen has extensive experience as CEO in international commercial operations within Life Science industry, including medical equipment and diagnostics. Torben has been a central part of Biotage AB’s successful international expansion during his time as CEO. Current board assignments include chairman of the board in Biotage and Genovis as well as board member in Medistim AS and Advanced Instruments PLC. Torben has been a board member of Boule since 2021, was born in 1952 and has a degree (B.Sc.) from Copenhagen Business School.

The nomination committee would like to express a big thank you to Yvonne Mårtensson for her significant contributions as board chairwoman and looks forward to her continued contribution as a board member of Boule.

Detailed information about the proposed board members can be found on Boule’s website.

The Nomination Committee’s complete proposal for a decision before the 2023 AGM as well as their reasoned statement will be submitted at the latest in connection with the publication of the notice to the AGM.

For more information, please contact:
Ulf Hedlundh, Chairman of the Nomination Committee, ulf.hedlundh”at”, 
phone +46 (0)8-440 37 70
Jesper Söderqvist, CEO and Group President, Boule Diagnostics AB, phone +46 (0)70-689 05 90
Jan Benjaminson, CFO, Boule Diagnostics AB,
phone +46 (0)70-666 93 88

About Boule Diagnostics AB (publ)
Boule Diagnostics AB is a global diagnostics company that develops, manufactures and markets instruments and consumable products for blood diagnostics. The company serves hospitals, clinics, laboratories and companies within blood diagnostics, in both human and veterinary hematology. The company operates via subsidiaries in Sweden, the USA, Mexico and Russia. The company products are sold globally primarily through distributors, supported by Boule’s own local sales and support personnel. The Boule shares are listed on Nasdaq Stockholm since 2011.

The information was submitted for publication, through the agency of the contact person set out above, at 12:15 CET on March 24, 2023.

Nomination Committee’s proposal for election of Board members of Boule Diagnostics AB 230324

  • Subscribe to our news